Clinical trial · no report yet · Phase 2
MorningSun
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
- NCT05207670 ↗
- Active not recruiting
- Genentech, Inc.
- 32 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 22 | |
| Podcasts | 6 | |
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Mosunetuzumab (Cohorts A-C); Mosunetuzumab (Cohorts D-E); Tocilizumab
- Arms
- Cohort A · Experimental
- Cohort B · Experimental
- Cohort C · Experimental
- Cohort D · Experimental
- Cohort E · Experimental
- Enrollment
- 320
- Primary outcomes
- Progression-free survival (PFS) rate at 24 months after the first study treatment (Cohorts A1, A2, and B)
- Objective response rate (ORR), defined as the proportion of participants with a complete metabolic response (CMR) or partial response (PR), as determined by the investigator according to the Lugano Criteria 2014 (Cohorts C, D, and E)
- Sponsor
- Genentech, Inc.
- Start
- Feb 1, 2022
- Primary completion
- Jul 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05207670 · updated Aug 31, 2026